Ratings Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Delayed Nyse Other stock markets 20:53:47 11/09/2024 BST			5-day change	1st Jan Change
16.89 ^USD	+1.26%		+3.71%	-11.39%

09-04	Transcript : Arcus Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM
08-27	Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital	MT

Summary: Arcus Biosciences, Inc.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Highlights: Arcus Biosciences, Inc.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Arcus Biosciences, Inc.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
With an enterprise value anticipated at 2.45 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: Arcus Biosciences, Inc.

Source: Surperformance

ESG chart: Arcus Biosciences, Inc.

Source: Refinitiv

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
ARCUS BIOSCIENCES, INC.	-	1.53B
LONZA GROUP AG		46.68B
IQVIA HOLDINGS INC.		42.88B
ALNYLAM PHARMACEUTICALS, INC.	-	32.89B
MODERNA, INC.	-	30.47B
CELLTRION, INC.		30.1B
ICON PUBLIC LIMITED COMPANY		23.23B
UNITED THERAPEUTICS CORPORATION		15.24B
BIO-TECHNE CORPORATION		11.7B
QIAGEN N.V.		10.2B
Average		24.49B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

D+

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes